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•  a description of the Registry and its goals;
•  cancer estimates for 2015;
•  a special section on skin melanoma;
•  brief summaries of recent/ongoing research projects;
•  a selected list of publications from 2014. 
In 2015, an estimated 6,400 Iowans will die from cancer, 18 times  the number caused by auto fatalities. Cancer and heart disease are  the leading causes of death in Iowa. These projections are based upon mortality data the State Health Registry of Iowa receives  from the Iowa Department of Public Health. The Registry has been  
recording the occurrence of cancer in Iowa since 1973, and is one  
of fourteen population-based registries and three supplementary 
registries nationwide providing data to the National Cancer  
Institute. With 2015 Cancer in Iowa the Registry makes a general  
report to the public on the status of cancer. This report will focus on:
	
The State Health Registry of Iowa  
The State Health Registry of Iowa is the best statewide resource for determining the burden  
of cancer on the Iowa population and assessing trends in the occurrence of cancer over time.  
Cancer is a reportable disease as stated in the Iowa Administrative 
Code. Cancer data are collected by the State Health Registry of 
Iowa, located at The University of Iowa in the College of Public 
Health’s Department of Epidemiology. The staff includes more than 
50 people. Half of them, situated throughout the state, regularly  
visit hospitals, clinics, and medical laboratories in Iowa and  
neighboring states to collect cancer data. A follow-up program 
tracks more than 99 percent of the cancer survivors diagnosed since 
1973. This program provides regular updates for follow-up and 
survival. The Registry maintains the confidentiality of the patients, 
physicians, and hospitals providing data.
In 2015 data will be collected on an estimated 16,900 new cancers 
among Iowa residents. In situ cases of bladder cancer are included  
in the estimates for bladder cancer, to be in agreement with the 
definition of reportable cases of the Surveillance, Epidemiology,  
and End Results (SEER) Program of the National Cancer Institute.  
Since 1973 the Iowa Registry has been funded by the SEER Program 
of the National Cancer Institute. Iowa represents rural and 
Midwestern populations and provides data included in many 
National Cancer Institute publications. Beginning in 1990 about  
5-10 percent of the Registry’s annual operating budget has been 
provided by the state of Iowa. Beginning in 2003, the University  
of Iowa has also been providing cost-sharing funds. The Registry  
also receives funding through grants and contracts with university, 
state, and national researchers investigating cancer-related topics.
THE GOALS OF THE 
REGISTRY ARE TO:
* assemble and report 
measurements of cancer 
incidence, survival, and  
mortality among Iowans;
* provide information on changes 
over time in the extent of 
disease at diagnosis, therapy, 
and patient survival;
* promote and conduct studies 
designed to identify factors 
relating to cancer etiology, 
prevention, and control;
*  respond to requests from 
individuals and organizations  
in the state of Iowa for cancer 
data and analyses; 
*  provide data and expertise for 
cancer research activities and 
educational opportunities. 
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Cancer Projections for 2015
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PROJECTED NUMBER OF CANCER DEATHS IN IOWA FOR 2015
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PROJECTED NUMBER OF NEW CANCERS IN IOWA FOR 2015
NEW CANCERS IN FEMALES
Type # of Cancers % of Total
Breast 2250 26.8
Lung 1000 11.9
Colon & Rectum 790 9.4
Uterus 610 7.3
Skin Melanoma 380 4.5
Non-Hodgkin Lymphoma 350 4.2
Thyroid 300 3.6
Leukemia 250 3.0 
Kidney & Renal Pelvis 230 2.7 
Pancreas 230 2.7 
All Others 2010 23.9
Total 8400
NEW CANCERS IN MALES
Type # of Cancers % of Total
Prostate 1700 20.0 
Lung 1270 15.0 
Colon & Rectum 840 9.9
Bladder  
(invasive and noninvasive) 640 7.5
Skin Melanoma 460 5.4
Non-Hodgkin Lymphoma 420 4.9
Kidney & Renal Pelvis 400 4.7
Leukemia 330 3.9
Oral Cavity 280 3.3
Pancreas 240 2.8
All Others 1920 22.6
Total 8500
CANCER DEATHS IN FEMALES
Type	 #	of	Cancers	 %	of	Total
Lung 760 25.3 
Breast 390 13.0
Colon & Rectum 290 9.7
Pancreas 200 6.6
Ovary 150 5.0
Leukemia 120 4.0
Non-Hodgkin Lymphoma 110 3.7
Uterus 110 3.7
Brain 70 2.3
Kidney & Renal Pelvis 60 2.0
All Others 740 24.7
Total 3000
CANCER DEATHS IN MALES
Type # of Cancers % of Total
Lung 970 28.6 
Prostate 320 9.4
Colon & Rectum 300 8.8
Pancreas 210 6.2
Leukemia 160 4.7
Non-Hodgkin Lymphoma 140 4.1
Esophagus 130 3.8
Bladder 130 3.8
Kidney & Renal Pelvis 130 3.8
Brain 110 3.2
All Others 800 23.6
Total 3400
Fortunately for Iowans, the chances of being diagnosed with many types of cancer can be reduced through 
positive health practices such as smoking cessation, physical exercise, healthful dietary habits, and alcohol 
consumption in moderation. Early detection through self-examination and regular health checkups can 
improve cancer survival.  
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Top 10 Types of Cancer in Iowa Estimated for 2015
6Skin melanoma is the 5th most 
commonly diagnosed cancer in 
both males and females in Iowa. 
Melanomas occur in other loca-
tions throughout the body, but 
the skin is by far the most com-
mon site. Therefore, throughout 
this section, the term melanoma 
will be used to refer to skin  
melanoma. The age-adjusted  
rates of melanoma have increased 
dramatically for both in situ  
(confined to the top layers of  
the skin known as the epidermis) 
and invasive (invasion into deeper 
layers of the skin known as the 
dermis, subcutis, and potentially 
other surrounding tissues)  
melanoma. The annual age-
adjusted incidence of invasive 
melanoma has quadrupled from 
6.5 cases per 100,000 population 
in 1974-1976, to 24.5 cases per 
100,000 population in 2010-2012 
(Figure 1). Likewise, the incidence 
of in situ melanoma has increased 
from almost no cases in 1974-1976 
to 13.7 cases per 100,000 popula-
tion in 2010-2012. Several factors 
have likely contributed to the 
increase, including increased 
exposure to ultraviolet (UV) light, 
heightened public awareness, and 
changes in reporting terminology 
among pathologists.   
Greater surveillance by health 
care providers may also be  
associated with the increased 
proportion of in situ melanomas 
relative to invasive melanomas. 
During the period 1973-1982,  
very few in situ melanomas were 
diagnosed, but by the period of 
2003-2012, in situ melanomas 
made up approximately one-third 
of all cases (Figure 2). Localized 
invasive melanomas (spread 
beneath top layer of skin, but not 
to lymph nodes or nearby tissues) 
make up over half of all melanoma 
cases, with regional (spread to 
nearby lymph nodes or tissues)  
and distant stages (spread to lymph 
nodes or organs far away from the 
original growth) each making up 
less than 10% of all melanomas.
While melanoma rates are highest 
among older adults, it is the 3rd 
most common cancer in adoles-
cents and young adults. The age-
adjusted rate of melanoma in 
those less than 40 years of age  
has more than doubled between 
1973 and 2012, with a current rate 
of 8.5 per 100,000 population  
(Figure 3). Adults ages 40-59 and 
60 and older have experienced 
even sharper increases in the rates 
of melanoma. In Iowa, as with the 
Skin Melanoma in Iowa
Figure 1.  ln situ and invasive melanoma incidence rates and melanoma mortality rates,  
 Iowa, 1974–2012.  
 (Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population)
Continued on page 8
7Figure 2. Frequency distribution of melanoma by stage, Iowa, 1973-2012.
Figure 3. Combined in situ and invasive melanoma incidence rates by age and gender, Iowa, 1973-2012.  
                    (Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population).
 (N=2,139)       (N=4,029)            (N=7,066)               (N=10,671)
1973-1982  1983-1992   1993-2002      2003-2012 
Continued on page 8
8United States in general, men have 
a higher rate of melanoma than 
women overall, but this varies by 
age. Among those less than age 
40, the rate of melanoma is 
higher for women; among those 
60 years of age or older, the rate 
is much higher for men.
Melanoma begins in melanocytes 
(pigment producing cells in the 
epidermis), and can occur on any 
skin surface. In Iowa cases from 
1973-2012, melanoma most often 
occured on the head or neck 
(30%), followed by the trunk 
(27%), upper limbs (23%), and 
lower limbs (17%). For those 
diagnosed under the age of 60, 
the trunk has been the more 
common site of melanoma among 
men, whereas the legs have been 
the more common site among 
women. For those diagnosed  
age 60 and older, the head or 
neck has been the most common 
site in both sexes.     
Overall, mortality rates for mela-
noma have been increasing, and 
melanoma has been the underly-
ing cause of death for 2,881 
Iowans between 1973 and 2012 
(Figure 1). Five-year relative  
survival for in situ melanoma is 
100%. Survival for localized and 
regional melanomas has increased 
from lows of 85% and 54% to 
97% and 70%, respectively  
(Figure 4). Survival for distant 
melanoma, however, has not 
improved over time, and remains 
at approximately 13%. These 
differences in survival by stage 
highlight the importance of early 
detection of melanoma.
As much as 90% of melanoma is 
estimated to be caused by  
UV exposure. People who have 
had one or more severe, blistering 
sunburns are at increased risk of 
melanoma. A 2004 study by the 
Environmental Protection Agency 
found that 44% of white adults in 
Iowa had at least one sunburn in 
the past year. The total amount  
of sun exposure over a lifetime  
is also a risk factor. In addition, 
studies have consistently shown 
that use of artificial sources of  
UV radiation, such as sunlamps 
and tanning booths, increases  
the risk of developing melanoma. 
The more a person uses indoor 
tanning booths, the greater the 
risk, and using tanning booths 
prior to age 35 increases the risk 
of melanoma by 59%. According 
to the 2010 National Health 
Interview Survey, nearly one in 
five women ages 18-29 reported 
having used a sunlamp, sunbed  
or tanning booth at least once  
in the 12 months preceding the 
survey, with Midwesterners 
reporting the greatest use of  
any region in the U.S. Specifically 
among non-Hispanic white 
women ages 18-25, 30% reported 
using indoor tanning.  
Figure 4. Relative 5-year survival for melanoma by stage, Iowa, 1973-2012.
9Having pale skin that burns easily, 
blue or gray eyes, red or blond 
hair, or many freckles increases 
the risk of melanoma. Melanoma 
can also sometimes run in families. 
Having two or more close relatives 
with melanoma (mother, father, 
sister, brother or child) can 
increase the risk of melanoma. 
Around 10% of all people with 
melanoma have a family history 
of the disease. Survivors of mela-
noma are nine times more likely 
than the general population to 
develop a new melanoma; 
approximately 5% of people who 
have had a melanoma in the past 
will eventually develop a second 
melanoma. In addition, people 
who have had other types of very 
common and much less aggressive 
skin cancers (basal cell or squa-
mous cell) have double the risk  
of developing additional basal  
cell or squamous cell cancers,  
or melanoma.
A nevus (mole) is a benign (non-
cancerous) tumor. Common moles 
are usually smaller than 6 mm 
(one quarter inch), with an even 
color, a round or oval shape, and  
a smooth surface. Although the 
majority of melanomas do not 
arise from a pre-existing nevus  
or mole, a dysplastic nevus may  
in some cases turn into cancer.  
A dysplastic nevus is generally 
bigger than a common mole and 
its color, surface and border may 
be different. It can have a mixture 
of different colors ranging from 
pink to dark brown, and is usually 
flat with a smooth, slightly scaly 
or pebbly surface with an irregu-
lar edge that may fade into the  
surrounding skin. Having more 
than 50 common moles also 
increases the risk for melanoma.  
Most moles, even dysplastic nevi, 
do not change into melanoma. 
But there are important signs  
to watch for, which are often 
referred to as “ABCDE”: 
Asymmetry (both asymmetry  
of shape and internal asymmetry 
of color), Border that is irregular, 
Color that is uneven, Diameter 
(size greater than a pencil eraser  
(6 mm)), and Evolving (the mole 
has changed over the past few 
weeks or months). Figure 5  
shows an example of an  
asymmetric melanoma with  
irregular borders and a length  
of 10 mm. 
Treatment for melanoma depends 
on the stage of disease, the size 
and location of the tumor, and 
the general health of the person. 
In most cases, the goal of treat-
ment is to remove or destroy the 
cancer completely. As previously 
discussed, most skin cancers can 
be cured if found and treated 
early. Surgery is the usual treat-
ment, but more advanced stages 
of melanoma may also involve 
chemotherapy, immunotherapy 
(medicines that stimulate a 
patient’s own immune system  
to recognize and destroy cancer 
cells) or radiation therapy.
There are steps that people can 
take to help prevent the 90%  
of melanomas caused by UV  
exposure, including the following: 
stay in the shade, especially  
during midday hours (10 AM to  
4 PM), wear clothing that covers 
up arms and legs, wear a hat with 
a wide brim to shade the face, 
head, ears and neck, wear  
sunglasses with UV protection,  
use sunscreen with sun protection 
factor (SPF) 30 or higher that is 
broad spectrum (protects against 
UVA and UVB rays) and is water 
resistant, and avoid indoor  
tanning. Of note, Iowa is one of 
only nine states that do not have 
laws or regulations related to 
indoor tanning, other than  
minimum requirements for  
operation of tanning facilities.  
Most other states have imple-
mented bans on indoor tanning 
for minors under a certain age, 
laws requiring parental accompa-
niment or parental permission,  
or harm-reduction regulations  
for all ages that require use of eye 
protection or limit exposure time.
There are also recommended 
approaches for early detection. 
Checking skin once per month can 
help detect new moles or changes 
in existing moles. Friends or  
family members can be helpful  
in checking the scalp and back. 
Regular skin exams by a health 
care professional qualified to 
diagnose skin cancer can also 
help detect melanoma early.  
Regular skin exams are  
particularly important for people 
with dysplastic nevi, a family 
history of melanoma, and those 
who have had melanoma in  
the past.
Figure 5. Asymmetric melanoma 
with irregular borders. 
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Research Projects During 2015
The State Health Registry of 
Iowa is participating in over 
60 open studies approved by 
the University of Iowa Human 
Subjects Office during 2015.  
Brief descriptions of a few of 
these studies are provided.
AGRICULTURAL HEALTH STUDY
The Agricultural Health Study 
(AHS) is a long-term study of 
agricultural exposures (including 
pesticides) and chronic disease 
(especially cancer) among 
commercial or private pesticide 
applicators (and their spouses, 
if married) in Iowa and North 
Carolina. The study is funded 
through the National Cancer 
Institute and involves several 
federal agencies. We are in the 
23rd year of the study.  
In the first five years, 89,658 
subjects (58,564 in Iowa and 
31,094 in North Carolina) were 
enrolled in the study. The total 
for Iowa included 31,877 private 
applicators, 21,771 spouses of 
private applicators, and 4,916 
commercial applicators.  
Enrollment consisted of 
completing questionnaires  
about past exposures and health. 
The second phase of the study  
for private applicators and their 
spouses was completed at the 
end of 2003. It involved a 
telephone interview, a mailed 
dietary questionnaire, and 
collection of a cheek cell sample 
from all consenting cohort 
members. The telephone 
interview asked about pesticide 
use since enrollment, current 
farming and work practices,  
and health changes. The dietary 
health questionnaire asked  
about cooking practices and 
types of foods eaten, since 
cooking practices and diet may 
play a role in cancer and other 
health conditions. The cheek cells 
are being used to understand 
possible links between genetics, 
exposures, and disease.   
For commercial applicators,  
the second phase of the study 
was completed at the end of 
2005. The study’s third phase 
began in 2005 and ended in 
2010. It involved updating 
information about exposures  
and health. The fourth phase  
of the study began in the fall  
of 2011 and for the University  
of Iowa research team primarily 
involves collection of blood  
and urine samples from a  
select subgroup of AHS male  
participants and collection of 
cheek cells from AHS participants 
diagnosed with cancer.       
Since 1997, cohort members 
have been linked annually or 
biennially to mortality and  
cancer registry incidence 
databases in both states.   
In addition, mortality data on  
the cohort are being obtained 
from the National Death Index.  
More information about results 
from this study, the study 
background, frequently asked 
questions, other resources 
(internet & telephone) for 
agricultural health information, 
references for publications 
to date, and information for 
scientific collaborators can be 
found at the website, http://
aghealth.nci.nih.gov/. This study’s 
data have also been pooled with 
data from other cohort studies 
and analyzed as collaborative 
activities. The titles for over  
200 publications from this study 
linked to PubMed are available  
at the website. The cancer-
related references for 2014 
publications are provided in  
the last section of this report.  
AYA HOPE STUDY
The Adolescent and Young Adult 
(AYA) Health Outcomes and 
Patient Experience (HOPE) Study 
is another ongoing example of a 
cancer survivor study. This study 
is an initial step in addressing 
potential factors related to gaps 
in research, care, and outcomes.  
From 7 SEER Registries across 
the United States, 525 patients 
(40 in Iowa), 15-39 years old 
at diagnosis between July 1, 
2007 and October 31, 2008 
have been enrolled with any of 
the following cancers: ovarian 
or testicular cancer, Hodgkin 
lymphoma, non-Hodgkin 
lymphoma, acute lymphoblastic 
leukemia, or selected types of 
sarcoma. Those who responded 
were representative of all AYA 
cancer survivors during this time 
period. 91% of the 525 have 
completed a subsequent survey 
8 to 17 months after the initial 
survey to obtain additional 
follow-up information regarding 
their cancer survivorship 
experience. During 2014, 
publications that have reported 
findings from this study are 
provided in the last section of 
this report.  
IOWA WOMEN’S  
HEALTH STUDY
This is a population-based cohort 
of 41,837 Iowa women, aged 
55-69, who were recruited in 
1986 to determine whether diet, 
body fat distribution, and other 
risk factors are related to cancer 
incidence. Exposure and lifestyle 
information was collected in a 
baseline mailed survey and in 
several follow-up mailed surveys. 
Mortality and cancer incidence 
have been ascertained since 1986 
through annual linkage to the 
State Health Registry of Iowa 
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databases and the National 
Death Index. In 2010 the study 
was refunded for its 25th 
through 29th years. Renewed 
funding is currently being 
sought. Over time, this has led  
to over 250 cancer-related 
publications, some of which 
occurred in 2014 and are listed  
in the references provided in  
the last section of this report.  
LUNG CANCER CARE 
OUTCOMES/SURVEILLANCE 
CONSORTIUM
This study involves a statistical 
coordinating center, the State 
Health Registry of Iowa, and five 
other primary data collection and 
research sites around the United 
States. Across these sites, we 
conducted population-based 
research in the areas of access  
to care and patterns of care  
for lung and colorectal cancer.  
In Iowa, this study was limited  
to lung cancer patients. We are 
evaluating the reasons for 
particular care decisions by 
patients and their physicians, 
including variation in 
disseminations of modern care 
protocols and practices  
in different geographic areas.   
We are also evaluating the 
effects of these decisions and 
practices on patient outcomes, 
including quality of life. Over 
1,000 newly diagnosed lung 
cancer patients were enrolled 
between June 2003 and March 
2005. Thereafter, these patients 
provided consent for medical 
record abstraction and 
participated in follow-up 
interviews. Several publications 
have resulted from the findings 
and those that occurred in 2014 
are provided in the last section  
of this report.  
NON-HODGKIN LYMPHOMA 
(NHL) CASE-CONTROL STUDY
The State Health Registry of Iowa 
(SHRI) with other investigators 
at the Mayo Clinic participated 
in a collaborative, population-
based case-control study of 
NHL involving researchers at 
the National Cancer Institute 
and three other Surveillance, 
Epidemiology, and End Results 
(SEER) registries. The main 
objective of the study was to 
better characterize risk factors 
for NHL. In Iowa, 364 live patients 
newly diagnosed with NHL 
between July 1, 1998 and June 
30, 2000 were enrolled.  
A similar number of population 
controls participated. Blood 
samples were sought from 
study participants. The SHRI 
also coordinated the acquisition 
of pathology reports, slides, 
and tissue blocks from all SEER 
centers. The slides were reviewed 
to determine the reliability of 
NHL pathologic classification.  
More recently, we collaborated 
with researchers to investigate 
whether genes with functional, 
common variant polymorphisms 
involved in immune function 
and regulation are associated 
with overall survival from NHL 
among these patients. To achieve 
this aim, medical record reviews 
were performed to obtain more 
detailed information on the 
treatment received for NHL.
This study’s data have also been 
pooled with data from other NHL 
case-control studies and analyzed 
as part of the InterLymph 
Consortium, a group of 
international investigators who 
discuss and undertake research 
activities with these data.   
All of these research activities 
resulted in several publications 
during 2014. The references for 
these are provided in the last 
section of this report.  
SECOND CANCER STUDIES 
INCLUDING THE  
WECARE STUDY
Over the past three decades, 
the State Health Registry of 
Iowa has participated in several 
second cancer studies. These 
have consisted of cohorts with a 
first cancer of the cervix, ovary, 
testis, uterus, female breast, 
non-Hodgkin lymphoma, or 
Hodgkin disease. They have been 
conducted in collaboration with 
the Radiation Epidemiology 
Branch at the National Cancer 
Institute and other registries 
in North America and Europe. 
Generally these studies evaluate 
the treatment received for the 
first cancer and the risk it places 
on the patient for development 
of a second cancer. They typically 
involve medical record review 
and pathology material retrieval. 
Currently, we are evaluating 
esophagus, pancreas, and stomach 
as second cancer sites in several of 
these cohorts, mentioned above, 
with a first cancer.    
The WECARE (Women’s 
Environmental Cancer and 
Radiation Epidemiology) 
Study is another example of a 
second cancer study. This study 
is designed to examine gene 
carrier status, demographic 
and lifestyle factors as well as 
environmental and treatment 
factors reported to be associated 
with an initial breast cancer as 
they relate to the development 
of a second breast cancer in the 
opposite breast. Eligible cases 
were diagnosed with a first 
breast cancer between 1985 
and 2009 that did not spread 
beyond the regional lymph 
nodes at diagnosis and a second 
primary contralateral breast 
cancer diagnosed at least one 
year after the first breast cancer 
diagnosis. Eligible controls were 
women with unilateral breast 
cancer who were individually 
matched to cases on year of 
birth, year of diagnosis, registry 
12
region, and race. The controls 
must have survived without any 
subsequent diagnosis of cancer 
and with an intact contralateral 
breast during the interval that 
elapsed between their matched 
case’s first and second breast 
cancer diagnoses. Data collection 
not only involved medical record 
review, but also participant 
interviews and biosample 
collection, either cheek cells 
or blood. The WECARE staff is 
collecting mammographic film 
data for its research subjects in 
2014 to evaluate breast density 
as another risk factor for a 
subsequent diagnosis of invasive 
breast cancer in the contralateral 
breast. A listing of publications 
during 2014 from second cancer 
studies, including the WECARE 
Study, is provided in the last 
section of this report.
SEER-MEDICARE
In the early 1990s, the cancer 
incidence and survival data from 
the State Health Registry of 
Iowa was combined with other 
SEER Registry data and linked to 
Medicare data. This linked data 
set has been updated on several 
occasions since and has become 
an important data resource 
for cancer research involving 
epidemiologic and health services 
research related to the diagnosis 
and treatment procedures, costs, 
and survival of cancer patients.  
Over the years many publications 
have resulted from this linked 
data set including several 
during 2014, which are listed 
at http://healthservices.cancer.
gov/seermedicare/overview/
publications.html.  
STUDIES INVOLVING TISSUE
Today, researchers are  
increasingly looking to obtain 
tissue to study molecular 
characteristics of cancers.  
Several studies that involve the 
State Health Registry of Iowa 
have included tissue. During 
2014, several articles involving  
de-identified tissue from Iowans 
were published, the references 
for which are provided in the  
last section of this report.      
TRANSPLANT CANCER  
MATCH STUDY
Solid organ transplantation 
provides life-saving treatment  
for end-stage organ disease,  
but is associated with 
substantially elevated cancer  
risk, largely due to the need  
to maintain long-term 
immunosuppression. Important 
questions remain concerning  
the role of immunosuppression 
and other factors in causing 
cancer in this setting. Staff at  
two federal agencies, the 
National Cancer Institute (NCI) 
and the Health Resources and 
Services Administration (HRSA), 
are creating a database through 
linkage of information during 
1987-2009 or beyond on over 
200,000 U.S. transplant recipients, 
wait list candidates (over 120,000 
in addition to those who were 
subsequently transplanted), and 
donors (over 60,000 deceased 
donors, over 50,000 living 
donors) with information on 
cancer from 15 U.S. cancer 
registries, including the State 
Health Registry of Iowa. These 
data are being used to conduct 
research concerning the spectrum 
of cancer risk in transplant 
recipients. The data will also be 
used by HRSA in its public health 
role overseeing the U.S. solid 
organ transplant network to 
maintain and improve safety of 
organ transplantation, and will 
allow NCI to better characterize 
the burden of cancer in this 
population and discover 
additional factors associated with 
cancer among this population.  
Several publications have 
resulted from the findings and 
those that occurred in 2014 are 
provided in the last section of 
this report.  
COOPERATIVE AGREEMENTS 
AND OTHER REGISTRIES
In the Midwest, the SHRI 
maintains cooperative 
agreements with several  
hospital cancer registries and 
other agencies/entities.   
Some of the latter include:
• Iowa Department of  
 Public Health
• Iowa Cancer Consortium 
• The University of Iowa
 – Center for Health Effects  
  of Environmental   
  Contamination
 – Center for Health Policy  
  and Research
 – Center for Public Health  
  Statistics
 – Environmental Health  
  Sciences Research Center
 – Health Effectiveness  
  Research Center
 – Holden Comprehensive  
  Cancer Center
 – Iowa Center for Agricultural  
  Safety and Health
 – Iowa Center for Education  
  and Research on Therapeutics  
  (Iowa CERT)
 – Injury Prevention Research  
  Center
 – Nutrition Center
 – Prevention Research Center  
  for Rural Health
 – Preventive Intervention  
  Center 
 – Reproductive Molecular  
  Epidemiology Research &  
  Education Program
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